Skip to main content

ACR 2017

Cost per Effectively Treated Patient with Sarilumab for Active, Moderate-to-Severe RA

Sarilumab Efficacy Maintained or Improved in Patients with RA Who Previously Received Sarilumab or Tocilizumab

Sustained Response in TARGET Study of Sarilumab + csDMARDs versus Placebo in RA Patients with Inadequate Response to TNF Inhibitors

Sarilumab + csDMARDs Effective Regardless of Baseline Disease Activity in RA Patients with Inadequate Response to TNF Inhibitors

Tocilizumab Monotherapy as Effective as TNF Inhibitors plus MTX in Patients with RA

ACR 2017, Conference Correspondent

An Updated Integrated Safety Analysis of Baricitinib for the Treatment of Moderate-to-Severe RA

ACR 2017, Conference Correspondent

Active Treatment Leads to Improved Myocardial Function in Patients with Active RA

ACR 2017, Conference Correspondent

Suboptimal EHR Reporting of Clinical Measures in RA Patients Receiving a Biologic or Targeted Synthetic DMARD

ACR 2017, Conference Correspondent

Both Tofacitinib and Baricitinib in Combination with Methotrexate Are Efficacious in Patients with RA

ACR 2017, Conference Correspondent

No Increased Cardiovascular Risk in Patients with RA Who Newly Initiated Tocilizumab versus Abatacept

Page 2 of 2
Results 11 - 20 of 20